FDA Approval for Opioid Withdrawal Tops AJPB Week in Review

Top news of the week from The American Journal of Pharmacy Benefits.

5. Reducing Opioid Duration More Effective in Curbing Misuse After Surgery

According to a new study, reducing prescription opioid duration, not dosage, may be more effective in curbing misuse after surgery. Read more.

4. Denosumab Can Benefit Patients with Glucocorticoid-Induced Osteoporosis

A study comparing denosumab (Prolia) with risedronate (Actone) found that denosumab could be a useful treatment option for patients newly initiating or continuing glucocorticoids who are at risk of fractures. Read more.

3. Autism Rates Linked to Allergic Conditions

A significant and positive association has linked common allergic conditions to autism spectrum disorder (ASD) in children. Read more.

2. Survey: Individuals Report Worsened Dry Eye Symptoms with Prolonged Screen Usage

As the age of technology continues to blossom, people are spending upwards of 10 hours per day looking at screens—4 hours longer than recommended by physicians. Read more.

1. FDA OKs Neurostimulation Device for Opioid Withdrawal

DyAnsys Inc. announced that its auricular neurostimulation device, Drug Relief, received clearance from the FDA. Read more.